Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 15Lymphoma 14Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large-Cell, Anaplastic 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Hodgkin Disease 3Hematologic Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2romidepsin 1prednylidene 1fludarabine phosphate 1fludarabine 1deltacortene 1Vorinostat 1Salvia hispanica seed extract 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1MLN 8237 1Lenalidomide 1Lactones 1Ki-1 Antigen 1Ifosfamide 1Diet, Gluten-Free 1Depsipeptides 1Carboplatin 1Bortezomib 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Enteropathy-Associated T-Cell Lymphoma × romidepsin × Clear all
NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Completed
22 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡